izpis_h1_title_alt

Genetic variability of the vitamin D receptor affects susceptibility to Parkinson's disease and dopaminergic treatment adverse events
ID Redenšek Trampuž, Sara (Avtor), ID Kristanc, Tilen (Avtor), ID Blagus, Tanja (Avtor), ID Trošt, Maja (Avtor), ID Dolžan, Vita (Avtor)

.pdfPDF - Predstavitvena datoteka, prenos (279,78 KB)
MD5: C54388CCDE61C42CFE19099F22E0E5FC
URLURL - Izvorni URL, za dostop obiščite https://www.frontiersin.org/articles/10.3389/fnagi.2022.853277/full Povezava se odpre v novem oknu

Izvleček
Vitamin D is a lipid-soluble molecule and an important transcriptional regulator in many tissues and organs, including the brain. Its role has been demonstrated also in Parkinson’s disease (PD) pathogenesis. Vitamin D receptor (VDR) is responsible for the initiation of vitamin D signaling cascade. The aim of this study was to assess the associations of VDR genetic variability with PD risk and different PD-related phenotypes. We genotyped 231 well characterized PD patients and 161 healthy blood donors for six VDR single nucleotide polymorphisms, namely rs739837, rs4516035, rs11568820, rs731236, rs2228570, and rs1544410. We observed that VDR rs2228570 is associated with PD risk (p < 0.001). Additionally, we observed associations of specific VDR genotypes with adverse events of dopaminergic treatment. VDR rs1544410 (GG vs. GA + AA: p = 0.005; GG vs. GA: p = 0.009) was associated with the occurrence of visual hallucinations and VDR rs739837 (TT vs. GG: p = 0.036), rs731236 (TT vs. TC + CC: p = 0.011; TT vs. TC: p = 0.028; TT vs. CC: p = 0.035), and rs1544410 (GG vs. GA: p = 0.014) with the occurrence of orthostatic hypotension. We believe that the reported study may support personalized approach to PD treatment, especially in terms of monitoring vitamin D level and vitamin D supplementation in patients with high risk VDR genotypes.

Jezik:Angleški jezik
Ključne besede:vitamin D receptor, Parkinson’s disease, biomarker, risk, susceptibility, adverse events, vitamin D, polymorphism
Vrsta gradiva:Članek v reviji
Tipologija:1.01 - Izvirni znanstveni članek
Organizacija:MF - Medicinska fakulteta
Status publikacije:Objavljeno
Različica publikacije:Objavljena publikacija
Leto izida:2022
Št. strani:9 str.
Številčenje:Vol. 14, art. 853277
PID:20.500.12556/RUL-145377 Povezava se odpre v novem oknu
UDK:616.8
ISSN pri članku:1663-4365
DOI:10.3389/fnagi.2022.853277 Povezava se odpre v novem oknu
COBISS.SI-ID:101668611 Povezava se odpre v novem oknu
Datum objave v RUL:19.04.2023
Število ogledov:301
Število prenosov:54
Metapodatki:XML RDF-CHPDL DC-XML DC-RDF
:
Kopiraj citat
Objavi na:Bookmark and Share

Gradivo je del revije

Naslov:Frontiers in aging neuroscience
Skrajšan naslov:Front. aging neurosci.
Založnik:Frontiers Media
ISSN:1663-4365
COBISS.SI-ID:20576008 Povezava se odpre v novem oknu

Licence

Licenca:CC BY 4.0, Creative Commons Priznanje avtorstva 4.0 Mednarodna
Povezava:http://creativecommons.org/licenses/by/4.0/deed.sl
Opis:To je standardna licenca Creative Commons, ki daje uporabnikom največ možnosti za nadaljnjo uporabo dela, pri čemer morajo navesti avtorja.

Sekundarni jezik

Jezik:Slovenski jezik
Ključne besede:nevrologija, Parkinsonova bolezen, receptor vitamina D, nevroznanost

Projekti

Financer:ARRS - Agencija za raziskovalno dejavnost Republike Slovenije
Številka projekta:P1-0170
Naslov:Molekulski mehanizmi uravnavanja celičnih procesov v povezavi z nekaterimi boleznimi pri človeku

Podobna dela

Podobna dela v RUL:
Podobna dela v drugih slovenskih zbirkah:

Nazaj